🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Chemomab today reported data from two study abstracts that will be presented as posters at EASL 2025, the @EASLNews #EASLCongress, that will be held May 7–10th, 2025, in Amsterdam, the Netherlands. For full details: bit.ly/4iAHWYs $CMMB

New analyses of primary sclerosing cholangitis (PSC) data from our Ph. 2 SPRING trial show that treatment with nebokitug is associated with dose-dependent and significant improvements in multiple inflammatory and fibrotic biomarkers. bit.ly/4iAHWYs $CMMB #EASLCongress

Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab, comments on new positive clinical data that supports nebokitug's impact on primary sclerosing cholangitis (PSC) and related diseases. Read more: bit.ly/4iAHWYs $CMMB #EASLCongress

Reported data from two study abstracts to be presented at the #EASLCongress further confirms the clinical potential of nebokitug as a first-in-class novel treatment for PSC and other fibro-inflammatory conditions. Read more: bit.ly/4iAHWYs $CMMB

Chemomab today announced that data from our Ph.2 SPRING trial of nebokitug (CM-101) in primary sclerosing cholangitis (PSC) was presented in a Distinguished Abstract Plenary session at Digestive Disease Week® 2025 in San Diego, CA. Read more: bit.ly/42KdhDE $CMMB #DDW25

Recently presented SPRING trial data from Digestive Disease Week® 2025 confirms the clinical potential of nebokitug as a first-in-class novel treatment for primary sclerosing cholangitis (PSC) and supports advancement to Phase 3. Read more: bit.ly/42KdhDE $CMMB #DDW25

Paul J. Pockros, MD, Director, Liver Disease Center Scripps Clinic, Director of the SC Liver Research Consortium, & SPRING trial investigator, presented positive Ph. 2 SPRING trial data at #DDW25. Read his comments on nebokitug’s clinical potential: bit.ly/42KdhDE $CMMB

SPRING trial data presented at #DDW25 shows that nebokitug at 15 and 48 weeks of treatment is well-tolerated & associated with significant improvements in multiple fibrotic & inflammatory biomarkers that may represent slowing of disease progression. bit.ly/42KdhDE $CMMB

Chemomab Therapeutics today announced financial and operating results for the first quarter ended March 31, 2025, and provided a corporate update. For details: bit.ly/4kpSBqv $CMMB

Dr. Adi Mor, Chemomab co-founder and CEO, will present a virtual corporate presentation on May 21st from 9:30 AM-10 AM ET during the Aegis Capital Corp. Virtual Conference. Institutional investors and registered representatives are invited to join: bit.ly/3S7zgy4 $CMMB

Dr. Adi Mor, Chemomab co-founder and CEO, will present a corporate presentation at BIOMED Israel 2025 in Tel Aviv, on May 21, 2025 in a session in Hall A from 12:15-14:15 IDT. For conference details, please visit: bit.ly/37xKmsD $CMMB